Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International    BAX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL
08/22 BAXTER INTERNATIONAL : Global Medical Nutrition Market Status and Forecast 2022 ..
08/22 BAXTER INTERNATIONAL : and ASPEN Announce Collaboration to Help Reduce Malnutrit..
08/21 BAXTER INTERNATIONAL : to Present at the Morgan Stanley 15th Annual Global Healt..
08/19 INSIDER TRADING ACTIVITY BAXTER INTE : BAX) – SVP Sold 12,670 shares of St..
08/15 BAXTER INTERNATIONAL : to Present at the Goldman Sachs 14th Annual European Medt..
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second-q..
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second q..
08/07 BAXTER INTERNATIONAL : Management's Discussion and Analysis of Financial Conditi..
08/03 BAXTER INTERNATIONAL : Reports Second-Quarter 2017 Results and Provides Updated ..
07/29 CLARIS LIFESCIENCES : completes sale of global injectables biz to Baxter
More news
News from SeekingAlpha
08/22 LIGAND : Situated For Growth
08/22 WALL STREET BREAKFAST : Strength In The Defense Sector
08/17 Premarket analyst action - healthcare
08/14 New positions at Third Point
08/13 Tracking Tweedy Browne Portfolio - Q2 2017 Update
Financials ($)
Sales 2017 10 493 M
EBIT 2017 1 675 M
Net income 2017 1 144 M
Debt 2017 16,2 M
Yield 2017 0,96%
P/E ratio 2017 32,37
P/E ratio 2018 25,80
EV / Sales 2017 3,23x
EV / Sales 2018 3,04x
Capitalization 33 864 M
Chart BAXTER INTERNATIONAL
Duration : Period :
Baxter International Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Technical analysis trends BAXTER INTERNATIONAL
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 66,9 $
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
Catherine R. Smith Chief Financial Officer, Director & Executive VP
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL40.17%33 864
MEDTRONIC PLC14.78%111 114
C R BARD INC42.18%23 272
ZIMMER BIOMET HOLDINGS INC10.43%23 042
HOYA CORPORATION27.62%22 361
TERUMO CORP-3.82%14 432